GeoVax Labs shares rise 10.25% premarket after announcing participation in Biotech Showcase and J.P. Morgan Healthcare Conference to highlight 2025 progress and 2026 strategic priorities.

GeoVax Labs, Inc. surged 10.25% in premarket trading following an announcement that senior management will showcase the company’s 2025 operational achievements, clinical progress, and strategic priorities at the Biotech Showcase 2026 and J.P. Morgan Healthcare Conference. The news highlighted advancements in its multi-antigen COVID-19 vaccine (CM04S1), oncolytic therapy (Gedeptin® for solid tumors), and GEO-MVA vaccine for mpox/smallpox, alongside manufacturing and partnership opportunities. The event, scheduled for January 12-15, 2026, underscores key clinical catalysts and regulatory milestones, reinforcing investor confidence in the firm’s pipeline and growth strategy. The positive premarket reaction aligns with the company’s emphasis on near-term inflection points and long-term value creation through its diverse therapeutic programs.